Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.75 |
| ▸ | HTR1A | P08908 | 2/20 | 0.75 |
| ▸ | HTR2A | P28223 | 2/20 | 0.75 |
| ▸ | DRD3 | P35462 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.65 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403558 | 0.94 | CHRM1 (0.89) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| Bromide SCHEMBL7405022 | 0.93 | CHRM1 (0.87) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL6404540 | 0.86 | PLD1 (0.81) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL5773820 | 0.86 | CHRM1 (0.75) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL3671916 | 0.84 | CHRM1 (0.72) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL5984495 | 0.84 | CYP2D6 (0.85) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL6404859 | 0.83 | CHRM1 (0.88) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL5777954 | 0.82 | OPRM1 (0.77) | CHRM1DRD2KCNH2HTR1AHTR2A | |
| SCHEMBL2993173 | 0.82 | CYP2D6 (0.73) | CHRM1DRD2KCNH2CHRM5HTR1A | |
| SCHEMBL2982735 | 0.82 | CHRM1 (0.71) | CHRM1DRD2KCNH2CHRM5HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 442 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | claimed |
| EP-2310973-A2 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-20 | — | — | EP | claimed |
| EP-2151777-A1 | Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-10 | — | — | EP | claimed |
| WO-2010012811-A2 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-3749325-B1 | DREADD ACTUATORS | US HEALTH (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025093572-A1 | SOLID DISPERSION COMPOSITIONS AND USES THEREOF | TRx Biosciences Limited (GB) | 2025-05-08 | — | — | WO | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250140406-A1 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | INSIGHT MOLECULAR DIAGNOSTICS INC. | 2025-05-01 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240408042-A1 | ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME | CLINICAL RES ASSOCIATES LLC (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11955208-B2 | Computational systems and methods for improving the accuracy of drug toxicity predictions | CORNELL UNIVERSITY (US) | 2024-04-09 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4304554-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | Aquestive Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230414452-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4277611-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11806311-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-09-07 | — | — | US | disclosed |
| US-11739063-B2 | DREADD actuators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4208155-A1 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149304-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145752-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023076281-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230131450-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230059204-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | Pike Therapeutics Inc. (CA) | 2023-02-23 | — | — | US | disclosed |
| EP-4135712-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | Pike Therapeutics, Inc. (CA) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023012691-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PHARMACEUTICAL AGENTS | PIKE THERAPEUTICS, INC. (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11541002-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220415451-A1 | COMPUTATIONAL SYSTEMS AND METHODS FOR IMPROVING THE ACCURACY OF DRUG TOXICITY PREDICTIONS | CORNELL UNIVERSITY (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220392580-A1 | COMPUTATIONAL MODEL TRAINED TO PREDICT INTERACTING PAIRS BASED ON WEAKLY-CORRELATED FEATURES | CORNELL UNIVERSITY (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220347117-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2022-11-03 | — | — | US | disclosed |
| US-11462303-B2 | Computational systems and methods for improving the accuracy of drug toxicity predictions | CORNELL UNIVERSITY (US) | 2022-10-04 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022192476-A1 | DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022187556-A1 | THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING MAGNETIZABLE NANOPARTICLES | VRG STEM CELL SERVICES INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | US | disclosed |
| WO-2022155544-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS INC (CA) | 2021-10-21 | — | — | US | disclosed |
| WO-2021209815-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | PIKE THERAPEUTICS, INC. (CA) | 2021-10-21 | — | — | WO | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3846778-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | Aquestive Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2021097247-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210145731-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| WO-2021087359-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | AQUESTIVE THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3811371-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | Aquestive Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200399228-A1 | DREADD ACTUATORS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-12-24 | — | — | US | disclosed |
| EP-3749325-A1 | DREADD ACTUATORS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200345624-A1 | Nanopore Delivery Device | HUDSON LEE EDWARD (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3692989-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10709668-B2 | Sprinkle formulations of acamprosate | CONFLUENCE PHARMACEUTICALS, LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200101009-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-04-02 | — | — | US | disclosed |
| US-20190350934-A1 | COMPOSITIONS AND METHODS FOR TREATING CHEMOSENSORY DYSFUNCTION | CYRANO THERAPEUTICS, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190295685-A1 | COMPUTATIONAL ANALYSIS FOR PREDICTING BINDING TARGETS OF CHEMICALS | CORNELL UNIVERSITY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-15 | — | — | US | disclosed |
| US-20190252036-A1 | COMPUTATIONAL SYSTEMS AND METHODS FOR IMPROVING THE ACCURACY OF DRUG TOXICITY PREDICTIONS | CORNELL UNIVERSITY (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019157083-A1 | DREADD ACTUATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190249173-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2019-08-15 | — | — | US | disclosed |
| US-10369340-B2 | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | NANOMEDICAL SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3510500-A1 | COMPUTATIONAL SYSTEMS AND METHODS FOR IMPROVING THE ACCURACY OF DRUG TOXICITY PREDICTIONS | Cornell University (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-2419091-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3482325-A1 | COMPUTATIONAL ANALYSIS FOR PREDICTING BINDING TARGETS OF CHEMICALS | Cornell University (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3452597-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | Wave Life Sciences Ltd. (SG) | 2019-03-13 | — | — | EP | disclosed |
| CN-109462995-A | The method and composition of bioactivator | 波涛生命科学有限公司 | 2019-03-12 | — | — | CN | disclosed |
| US-20190054024-A1 | Solid Dosage Forms | HUMANWELL PHARMACEUTICAL US, Inc. (US) | 2019-02-21 | — | — | US | disclosed |
| US-10206927-B2 | Compostions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190046458-A1 | SPRINKLE FORMULATIONS OF ACAMPROSATE | CONFLUENCE PHARMACEUTICALS LLC (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190002984-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2019-01-03 | — | — | US | disclosed |
| US-20180251840-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIV VIRGINIA PATENT FOUNDATION (US) | 2018-09-06 | — | — | US | disclosed |
| US-20180143187-A1 | Methods for Detection of Biological Substances | CYRANO THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-20180098970-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| WO-2018049376-A1 | COMPUTATIONAL SYSTEMS AND METHODS FOR IMPROVING THE ACCURACY OF DRUG TOXICITY PREDICTIONS | CORNELL UNIVERSITY (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-3291800-A1 | SPRINKLE FORMULATIONS OF ACAMPROSATE | Confluence Pharmaceuticals, LLC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-104546669-B | Nanochannel device and correlation technique | 得克萨斯大学体系董事会 | 2018-01-05 | — | — | CN | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319698-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2017-11-09 | — | — | US | disclosed |
| EP-3212167-A1 | GASTRORETENTIVE GEL FORMULATIONS | Jagotec AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106484-A | Gastric retention gel preparation | 雅戈泰克股份公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-103271083-B | Multi-functional ionic liquid compositions | 阿拉巴马大学 | 2017-08-11 | — | — | CN | disclosed |
| US-20170226585-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2017-08-10 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9719988-B2 | Methods for detection of biological substances | CYRANO THERAPEUTICS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| EP-3156053-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20160376658-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2016-12-29 | — | — | US | disclosed |
| US-9526824-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2307011-B1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160338966-A1 | Multimicroparticulate pharmaceutical forms foe oral administration | FLAMEL TECHNOLOGIES (FR) | 2016-11-24 | — | — | US | disclosed |
| WO-2016179252-A1 | SPRINKLE FORMULATIONS OF ACAMPROSATE | CONFLUENCE PHARMACEUTICALS, LLC (US) | 2016-11-10 | — | — | WO | disclosed |
| EP-2355864-B1 | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-2083811-B1 | METHODS OF TREATING DOWN'S SYNDROME, FRAGILE X SYNDROME AND AUTISM | CLINICAL RES ASSOCIATES LLC (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| CN-105744983-A | Device and method for sustained release of low water solubility therapeutic agent in solubilizer | 纳米医学系统公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160175572-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3033138-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | Nanomedical Systems Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160139161-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA | 2016-05-19 | — | — | US | disclosed |
| WO-2016066256-A1 | GASTRORETENTIVE GEL FORMULATIONS | JAGOTEC AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| US-9308162-B2 | Biocompatible oligomer-polymer compositions | TOLMAR THERAPEUTICS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150366869-A1 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES | CYRANO THERAPEUTICS, INC. | 2015-12-24 | — | — | US | disclosed |
| WO-2015167760-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | CELANESE ACETATE LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150246174-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912070-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | Celanese Acetate LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| CN-101378736-B | Multiparticulate pharmaceutical dosage form for oral administration | FLAMEL TECHNOLOGIES (FR) | 2015-08-19 | — | — | CN | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9096743-B2 | Process for forming films, fibers, and beads from chitinous biomass | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812777-A | Polysaccharide ester microspheres and methods and articles related thereto | CELANESE ACETATE LLC | 2015-07-29 | — | — | CN | disclosed |
| US-9044443-B2 | Methods of treating autism | CLINICAL RESEARCH ASSOCIATES, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| CN-104546669-A | NANOCHANNELED DEVICE AND RELATED METHODS | UNIV TEXAS | 2015-04-29 | — | — | CN | disclosed |
| US-9005185-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-04-14 | — | — | US | disclosed |
| US-8968706-B2 | Methods for diagnosing and treating loss or distortion of taste | CYRANO THERAPEUTICS, INC. | 2015-03-03 | — | — | US | disclosed |
| WO-2015023557-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF LOW WATER SOLUBILITY THERAPEUTIC AGENT IN SOLUBILIZER | NANOMEDICAL SYSTEMS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2291174-B1 | FLOWABLE COMPOSITION COMPRISING BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| CN-102271732-B | Nanochannel devices and related methods | UNIV TEXAS | 2014-12-31 | — | — | CN | disclosed |
| CN-104203220-A | Device and method for sustained release of therapeutic agent | UNIV TEXAS | 2014-12-10 | — | — | CN | disclosed |
| US-20140348936-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-27 | — | — | US | disclosed |
| US-20140328884-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140315720-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2790677-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2790678-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | Celanese Eva Performance Polymers, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2770984-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140206734-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140193891-A1 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES | CYRANO THERAPEUTICS, INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140180251-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014066463-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140113826-A1 | POLYSACCHARIDE ESTER MICROSPHERES AND METHODS AND ARTICLES RELATING THERETO | CELANESE ACETATE LLC (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2102208-B1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-23 | — | — | EP | disclosed |
| US-8697361-B2 | Serotonin transporter gene and treatment of alcoholism | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140073654-A1 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES | CYRANO THERAPEUTICS, INC. | 2014-03-13 | — | — | US | disclosed |
| US-8663938-B2 | Methods for detection of biological substances | CYRANO THERAPEUTICS, INC. | 2014-03-04 | — | — | US | disclosed |
| WO-2014031398-A1 | BIOMEDICAL DEVICES COMPRISING MOLDED POLYETHYLENE COMPONENTS | TICONA LLC (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140052264-A1 | Porous, Stabilized Craniomaxillofacial Implants and Methods and Kits Relating Thereto | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051771-A1 | Biomedical Devices Comprising Molded Polyethylene Components | TICONA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-8632510-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | NUVO RESEARCH INC. (CA) | 2013-12-19 | — | — | US | disclosed |
| US-20130331402-A1 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-12 | — | — | US | disclosed |
| US-8552054-B2 | Anticancer agents, viricides, psychological disorders | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130261186-A1 | Methods of Treating Autism | SEASIDE THERAPEUTICS, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130240483-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-19 | — | — | US | disclosed |
| CN-103271083-A | Multi-functional ionic liquid compositions | UNIV ALABAMA | 2013-09-04 | — | — | CN | disclosed |
| US-8513304-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-08-20 | — | — | US | disclosed |
| CN-101341135-B | Substituted pyrazinone derivatives for the treatment of MCH-1 mediated diseases | JANSSEN PHARMACEUTICA NV | 2013-08-14 | — | — | CN | disclosed |
| US-8506934-B2 | Methods for detection of biological substances | CYRANO THERAPEUTICS, INC. | 2013-08-13 | — | — | US | disclosed |
| US-8480637-B2 | Nanochanneled device and related methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-07-09 | — | — | US | disclosed |
| WO-2013090893-A1 | GASTRORETENTIVE CONTROLLED RELEASE VEHICLES THAT INCLUDE ETHYLENE COPOLYMERS, ETHYL CELLULOSES, AND/OR THERMPOPLASTIC POLYURETHANES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090891-A1 | CONTROLLED RELEASE VEHICLES HAVING DESIRED VOID VOLUME ARCHITECTURES | CELANESE EVA PERFORMANCE POLYMERS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-8460867-B2 | Methods of treating psychosis and schizophrenia based on polymorphisms in the CNTF gene | NOVARTIS AG (CH) | 2013-06-11 | — | — | US | disclosed |
| CN-101326275-B | Multifunctional ionic liquid composition | UNIV ALABAMA | 2013-06-05 | — | — | CN | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130131628-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063004-A1 | DEVICE AND METHOD FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2255184-B1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | Univ Virginia Patent Found (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2578216-A1 | Methods of treating fragile x syndrome | Seaside Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130079404-A1 | TOPICAL FORMULATION | NUVO RESEARCH INC. (CA) | 2013-03-28 | — | — | US | disclosed |
| EP-2567696-A1 | Compositions for treating autism spectrum disorder | Seaside Therapeutics, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-1966164-B1 | NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | disclosed |
| CN-101277684-B | Microparticles for the modified release of at least one active principle and oral pharmaceutical forms containing them | FLAMEL TECH SA | 2013-02-27 | — | — | CN | disclosed |
| EP-2556830-A1 | Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130012587-A1 | Methods of Treating Autism | SEASIDE THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012586-A1 | Methods of Treating Fragile X Syndrome | SEASIDE THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130011849-A1 | Methods for Detection of Biological Substances | CYRANO THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8343962-B2 | Topical formulation | NUVO RESEARCH INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-20120302592-A1 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| CN-102802631-A | Dosing regimen associated with long-acting injectable paliperidone esters | JANSSEN PHARMACEUTICA NV | 2012-11-28 | — | — | CN | disclosed |
| US-8314077-B2 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-101541796-B | Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA NV | 2012-11-07 | — | — | CN | disclosed |
| US-8293489-B2 | Methods for detection of biological substances | CYRANO THERAPEUTICS, INC. | 2012-10-23 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8278276-B2 | Methods of treating autism | SEASIDE THERAPEUTICS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8273715-B2 | Methods of treating fragile X syndrome | SEASIDE THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| EP-2493473-A1 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS | Janssen Pharmaceutica NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220962-A1 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF VITAMINS USING BASIC PERMEATION ENHANCERS | TECHNOLOGY RECOVERY SYSTEMS, LLC (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120129940-A1 | METHODS OF TREATING AUTISM | SEASIDE THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122986-A1 | Methods of Treating Fragile X Syndrome | SEASIDE THERAPEUTICS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120115729-A1 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115149-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1423107-B1 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARM INC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120095443-A1 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-04-19 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8143311-B2 | Methods of treating fragile X syndrome and autism | SEASIDE THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2425013-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | University Of Virginia Patent Foundation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2419091-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009646-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011150380-A1 | METHODS OF TREATMENT OF FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294879-A1 | METHOD OF TREATMENT OF FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| CN-102225046-A | Transdermal drug delivery formulation | NUVO RES INC | 2011-10-26 | — | — | CN | disclosed |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | TOLMAR THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8012496-B2 | Gastric retention controlled drug delivery system | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2011-09-06 | — | — | US | disclosed |
| EP-2355864-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | The Board of Regents of The University of Texas System (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-07-28 | — | — | US | disclosed |
| EP-2347015-A2 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GENE | Janssen Pharmaceutica, N.V. (BE) | 2011-07-27 | — | — | EP | disclosed |
| CN-101296691-B | Transdermal drug delivery dosage form | NUVO RES INC | 2011-07-27 | — | — | CN | disclosed |
| EP-2344162-A2 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-07-20 | — | — | EP | disclosed |
| US-7976871-B2 | Modified release composition of highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2011-07-12 | — | — | US | disclosed |
| US-20110166166-A1 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES | CYRANO THERAPEUTICS, INC. | 2011-07-07 | — | — | US | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20110124657-A1 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-26 | — | — | US | disclosed |
| US-20110112159-A1 | SEROTONIN TRANSPORTER GENE AND TREAMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110104266-A1 | MULTIMICROPARTICULATE PHARMACEUTICAL FORMS FOR ORAL ADMINISTRATION | FLAMEL TECHNOLOGIES (FR) | 2011-05-05 | — | — | US | disclosed |
| WO-2011053829-A1 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS | JANSSEN PHARMACEUTICAL NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110105536-A1 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2310973-A2 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-20 | — | — | EP | disclosed |
| EP-2307011-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| CN-102016571-A | Serotonin transporter gene and treatment of alcoholism | UNIV VIRGINIA | 2011-04-13 | — | — | CN | disclosed |
| EP-1458888-B1 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE | NOVARTIS AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-03-17 | — | — | US | disclosed |
| EP-2291174-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | Tolmar Therapeutics, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20110028460-A1 | TOPICAL FORMULATION | FQUBED, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2010141470-A2 | PROCESS FOR FORMING FILMS, FIBERS, AND BEADS FROM CHITINOUS BIOMASS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100305208-A1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2010-12-02 | — | — | US | disclosed |
| EP-2255184-A2 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | University Of Virginia Patent Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| CN-1520286-B | Gastric retention controlled drug delivery system | SUN PHARMA INC LTD | 2010-12-01 | — | — | CN | disclosed |
| WO-2010126603-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010120817-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-21 | — | — | WO | disclosed |
| US-7816398-B2 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2238975-A1 | Gastric retention controlled drug delivery system | Sun Pharma Advanced Research Company Ltd (IN) | 2010-10-13 | — | — | EP | disclosed |
| US-20100227875-A1 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES | CYRANO THERAPEUTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| WO-2010096117-A2 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GENE | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-26 | — | — | WO | disclosed |
| CN-101810592-A | Contain the pharmaceutical preparation that is dispersed in the active matter in the substrate | ALTANA PHARMA AG | 2010-08-25 | — | — | CN | disclosed |
| EP-1411901-B1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | SUN PHARMA ADVANCED RES CO LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| US-7776345-B2 | Gastric retention controlled drug delivery system | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2010-08-17 | — | — | US | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152699-A1 | Nanochanneled Device and Related Methods | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2013202-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
| US-20100144781-A1 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GENE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-10 | — | — | US | disclosed |
| WO-2010056986-A2 | NANOCHANNELED DEVICE AND RELATED METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2010-04-29 | — | — | US | disclosed |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-03-25 | — | — | US | disclosed |
| EP-1966191-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-17 | — | — | EP | disclosed |
| CN-101663028-A | Combined effect of topiramate and ondansetron on alcohol consumption | UNIV VIRGINIA | 2010-03-03 | — | — | CN | disclosed |
| US-7670849-B2 | Method for diagnosing insulin resistance from nasal secretions | CYRANO THERAPEUTICS, INC. | 2010-03-02 | — | — | US | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-02-18 | — | — | US | disclosed |
| EP-2091942-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-17 | — | — | EP | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| EP-2151777-A1 | Method for screening of 5HT7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029770-A1 | Methods of treating mental retardation, down's syndrome, fragile X syndrome and autism | SEASIDE THERAPEUTICS, LLC (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010012817-A2 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. | 2010-02-04 | — | — | US | disclosed |
| WO-2010012811-A2 | METHOD FOR SCREENING OF 5HT7 RECEPTOR LIGANDS BASED ON A NEW PHARMACOPHORE MODEL AND A DESCRIPTOR'S PROFILE FILTER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| EP-2149373-A1 | 5HT7 receptor ligands and compositions comprising the same | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090317453-A1 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF DRUGS USING BASIC PERMEATION ENHANCERS | DERMATRENDS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318520-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS DRIVE (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009155139-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | AFECTA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009148581-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | QLT USA, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2124909-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | University Of Virginia Patent Foundation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
| CN-100548290-C | Sulfamate derivatives is used for the treatment of the purposes of impulse control disorder | UNIV CINCINNATI (US) | 2009-10-14 | — | — | CN | disclosed |
| US-20090239908-A1 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| EP-2102208-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-23 | — | — | EP | disclosed |
| CN-101541796-A | Novel substituted diaza spiro pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-23 | — | — | CN | disclosed |
| WO-2009108837-A2 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | disclosed |
| CN-101522660-A | Substituted pyrazinone derivatives for use as a medicine | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-02 | — | — | CN | disclosed |
| EP-2091942-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090197849-A1 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF DRUGS USING BASIC PERMEATION ENHANCERS | DERMATRENDS, INC. | 2009-08-06 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2083811-A1 | METHODS OF TREATING MENTAL RETARDATION, DOWN'S SYNDROME, FRAGILE X SYNDROME AND AUTISM | Seaside Therapeutics, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| CN-101448795-A | Substituted pyrazinone derivatives for use as a medicine | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-03 | — | — | CN | disclosed |
| CN-101426788-A | Substituted pyrazinone derivatives for use as a medicine | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | CN | disclosed |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009029308-A1 | MEDICATION COMBINATIONS FOR THE TREATMENT OF ALCOHOLISM AND DRUG ADDICTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-2029553-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | Janssen Pharmaceutica, N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| CN-101378736-A | Multiparticulate pharmaceutical dosage form for oral administration | FLAMEL TECH SA (FR) | 2009-03-04 | — | — | CN | disclosed |
| EP-2013202-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-14 | — | — | EP | disclosed |
| CN-101346368-A | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | CN | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
| CN-101341135-A | Novel substituted pyrazinone derivatives for the treatment of MCH-1 mediated diseases | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-07 | — | — | CN | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| CN-101326275-A | Multifunctional ionic liquid composition | UNIV ALABAMA (US) | 2008-12-17 | — | — | CN | disclosed |
| EP-1986616-A2 | MICROPARTICULATE PHARMACEUTICAL FORMS RESISTANT TO IMMEDIATE RELEASE OF THE ACTIVE PRINCIPLE IN THE PRESENCE OF ALCOHOL | Flamel Technologies (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| CN-101296691-A | transdermal drug delivery dosage form | NUVO RES INC (CA) | 2008-10-29 | — | — | CN | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7429577-B2 | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation | COMPREHENSIVE NEUROSCIENCE, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1966164-A1 | NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | Janssen Pharmaceutica, N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| EP-1966191-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008095086-A2 | TOPIRAMATE PLUS NALTREXONE FOR THE TREATMENT OF ADDICTIVE DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008077092-A2 | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON ALCOHOL CONSUMPTION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153899-A1 | FATTY AMINE DRUG CONJUGATES | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | disclosed |
| EP-1931760-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | The University of Alabama (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008068265-A1 | NOVEL SUBSTITUTED DIAZA SPIRO PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008066750-A1 | METHODS OF TREATING MENTAL RETARDATION, DOWN'S SYNDROME, FRAGILE X SYNDROME AND AUTISM | SEASIDE THERAPEUTICS, LLC (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008043775-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-17 | — | — | WO | disclosed |
| US-20080090803-A1 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007135131-A9 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-20080027106-A1 | METHODS OF TREATING PSYCHOSIS AND SCHIZPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE | NOVARTIS AG (CH) | 2008-01-31 | — | — | US | disclosed |
| WO-2007141200-A1 | NOVEL N-ARYL AND N-HETEROARYL SUBSTITUTED PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | WO | disclosed |
| CN-101084201-A | Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-05 | — | — | CN | disclosed |
| WO-2007135131-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| US-20070264346-A1 | Multimicroparticulate pharmaceutical forms for oral administration | FLAMEL TECHNOLOGIES (FR) | 2007-11-15 | — | — | US | disclosed |
| WO-2007122173-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007093642-A2 | MICROPARTICULATE PHARMACEUTICAL FORMS RESISTANT TO IMMEDIATE RELEASE OF THE ACTIVE PRINCIPLE IN THE PRESENCE OF ALCOHOL | FLAMEL TECHNOLOGIES (FR) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191440-A1 | Methods of treating autism and fragile X syndrome | SEASIDE THERAPEUTICS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007071639-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071646-A1 | NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| CN-1964713-A | Co-use of dopamine-receptor binding compounds | DARPHARMA INC (US) | 2007-05-16 | — | — | CN | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | disclosed |
| US-7199151-B2 | DHA-pharmaceutical agent conjugates of taxanes | LUITPOLD PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060275801-A1 | Methods for detection of biological substances | CYRANO THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006119292-A2 | METHODS FOR DETECTION OF BIOLOGICAL SUBSTANCES | HENKIN, ROBERT (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060210633-A1 | Programmed drug delivery system | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-09-21 | — | — | US | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | disclosed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | disclosed |
| EP-1423107-A4 | FATTY ALCOHOL DRUG CONJUGATES | LUITPOLD PHARM INC (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1427407-A4 | FATTY AMINE DRUG CONJUGATES | LUITPOLD PHARM INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20050096305-A1 | Augmentation of antipsychotic agent pharmacotherapy with chromium picolinate supplementation | COMPREHENSIVE CLINICAL DEVELOPMENT, INC. (FKA COMPREHENSIVE NEUROSCIENCE, INC.) | 2005-05-05 | — | — | US | disclosed |
| EP-1158973-B1 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIV CINCINNATI (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20050074487-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050059006-A1 | Using presence of polymorphism in ciliary neurotrophic factor (CNTF) gene sequences as diagnostic indicator for lloperidone treatment of psychotic disorders | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| WO-2004108067-A2 | PROGRAMMED DRUG DELIVERY SYSTEM | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2004-12-16 | — | — | WO | disclosed |
| US-6831077-B2 | Administering to a patient suffering from psychological disorder, an antipsychotic agent in combination with a chromium picolinate, for minimizing side effects in a patient taking an atypical antipsychotic agent | COMPREHENSIVE NEUROSCIENCE, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040220262-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2004-11-04 | — | — | US | disclosed |
| EP-1466628-A1 | DHA-pharmaceutical agent conjugates | Luitpold Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1458888-A2 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE | Novartis AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20040180088-A1 | Gastric retention controlled drug delivery system | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2004-09-16 | — | — | US | disclosed |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | PROTARGA, INC. | 2004-09-16 | — | — | US | disclosed |
| CN-1523980-A | Pharmaceutical formulations containing an active dispersed in a matrix | ��̹��ҽҩ��˾ | 2004-08-25 | — | — | CN | disclosed |
| CN-1520286-A | Gastric retention controlled drug delivery system | ̫��ҽҩ��ҵ����˾ | 2004-08-11 | — | — | CN | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| EP-1427407-A2 | FATTY AMINE DRUG CONJUGATES | Protarga Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040106589-A1 | Fatty acid-pharmaceutical agent conjugates | PROTARGA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| EP-1423107-A2 | FATTY ALCOHOL DRUG CONJUGATES | Protarga, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1411901-A1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | Sun Pharmaceuticals Industries Ltd. (IN) | 2004-04-28 | — | — | EP | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| WO-2004011007-A1 | AUGMENTATION OF ATYPICAL ANTIPSYCHOTIC AGENT PHARMACOTHERAPY WITH CHROMIUM SUPPLEMENTATION | COMPREHENSIVE NEUROSCIENCE, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019030-A1 | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation | COMPREHENSIVE CLINICAL DEVELOPMENT, INC. (FKA COMPREHENSIVE NEUROSCIENCE, INC.) | 2004-01-29 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-6602902-B2 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | PROTARGA, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030124176-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003054226-A2 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON A POLYMORPHISM IN THE CTF GENE | NOVARTIS AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030104041-A1 | Transdermal and topical administration of drugs using basic permeation enhancers | DERMATRENDS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030065023-A1 | Fatty amine drug conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030059471-A1 | Oral delivery formulation | COMPTON BRUCE JON (US) | 2003-03-27 | — | — | US | disclosed |
| WO-2003011255-A1 | GASTRIC RETENTION CONTROLLED DRUG DELIVERY SYSTEM | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-02-13 | — | — | WO | disclosed |
| US-20020192300-A1 | Transdermal and topical administration of antipsychotic agents using basic enhancers | DERMATRENDS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020177609-A1 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-28 | — | — | US | disclosed |
| CN-1377282-A | Fatty acid-anticancer conjugates and uses thereof | PROTARGA INC (US) | 2002-10-30 | — | — | CN | disclosed |
| WO-2002076402-A2 | FATTY AMINE DRUG CONJUGATES | PROTARGA, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002076404-A2 | FATTY ALCOHOL DRUG CONJUGATES | PROTARGA, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| CN-1360500-A | Use of sulfamate derivatives for the treatment of impulse control disorders | UNIV CINCINNATI (US) | 2002-07-24 | — | — | CN | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | LUITPOLD PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| EP-1163011-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | Protarga Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| EP-1158973-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | disclosed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-0669331-B1 | Benzodioxane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | CHRM1 3355/4885DRD2 3631/4885KCNH2 3716/4885 |
| US-20020177609-A1 | Fatty alcohol drug conjugates | ADH1A, ADH1C, ADH5 | CHRM1 4096/4885DRD2 301/4885KCNH2 3644/4885 |
| US-10709668-B2 | Sprinkle formulations of acamprosate | SI, SLC10A2, SLC10A1 | CHRM1 1415/4885DRD2 3831/4885KCNH2 4829/4885 |
| US-20150306230-A1 | DRUG DELIVERY VEHICLES COMPRISING CELLULOSE DERIVATIVES, STARCH DERIVATIVES, AND COMBINATIONS THEREOF | PGRMC2, PGRMC1, CYP3A43 | CHRM1 1818/4885DRD2 1630/4885KCNH2 3000/4885 |
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM1 4575/4885DRD2 4644/4885KCNH2 4339/4885 |
| US-20110245172-A1 | BIOCOMPATIBLE OLIGOMER-POLYMER COMPOSITIONS | BMP2, CHERP, PUF60 | CHRM1 1551/4885DRD2 3487/4885KCNH2 4549/4885 |
| US-10619209-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1501/4885DRD2 23/4885KCNH2 1457/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | CHRM1 3355/4885DRD2 3631/4885KCNH2 3716/4885 |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1501/4885DRD2 23/4885KCNH2 1457/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CHRM1 1417/4885DRD2 59/4885KCNH2 1523/4885 |
| US-20020010208-A1 | Targeting a pharmaceutical agent to a noncentral nervous system tissue by administering a covalent conjugate of the drug and cis-docosahexanoic acid | FABP7, FADS2, ALOX5 | CHRM1 2229/4885DRD2 1420/4885KCNH2 4553/4885 |
| US-20100029620-A1 | SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | CHRM1 46/4885DRD2 42/4885KCNH2 1108/4885 |
| US-20180251840-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1842/4885DRD2 31/4885KCNH2 1603/4885 |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | MCHR1, MCHR2, MC1R | CHRM1 87/4885DRD2 309/4885KCNH2 2121/4885 |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | CHRM1 131/4885DRD2 1/4885KCNH2 785/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1501/4885DRD2 23/4885KCNH2 1457/4885 |
| US-20110065628-A1 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction | SLC6A3, SLC6A4, ADH5 | CHRM1 869/4885DRD2 11/4885KCNH2 945/4885 |
| US-20130012586-A1 | Methods of Treating Fragile X Syndrome | GABRB1, GABBR1, GABBR2 | CHRM1 1690/4885DRD2 1473/4885KCNH2 1269/4885 |
| US-20210128511-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | ADRA2C, ADRB3, ADRA2B | CHRM1 420/4885DRD2 676/4885KCNH2 1848/4885 |
| US-20190249255-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1842/4885DRD2 31/4885KCNH2 1603/4885 |
| US-20230277448-A1 | CHEWABLE FORMULATIONS | SI, TAS2R39, TAS2R31 | CHRM1 1038/4885DRD2 3006/4885KCNH2 2276/4885 |
| US-20100041689-A1 | Combined Effects of Topiramate and Ondansetron on Alcohol Consumption | SLC6A3, SLC6A4, HTR5A | CHRM1 1295/4885DRD2 12/4885KCNH2 1239/4885 |
| US-11739063-B2 | DREADD actuators | GRK1, GRK3, GRK2 | CHRM1 32/4885DRD2 373/4885KCNH2 1958/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CHRM1 4394/4885DRD2 4801/4885KCNH2 4612/4885 |
| US-20240408042-A1 | ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME | GABBR2, GABBR1, GABRB2 | CHRM1 1774/4885DRD2 583/4885KCNH2 360/4885 |
| US-20220233471-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | CYP2C19, PAICS, CYP2B6 | CHRM1 843/4885DRD2 3087/4885KCNH2 2528/4885 |
| US-20140206734-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1842/4885DRD2 31/4885KCNH2 1603/4885 |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | CHRM1 31/4885DRD2 37/4885KCNH2 419/4885 |
| US-20090111801-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, ADRB2, CHRNA5 | CHRM1 32/4885DRD2 39/4885KCNH2 353/4885 |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1501/4885DRD2 23/4885KCNH2 1457/4885 |
| US-20210322447-A1 | TRANSDERMAL MICRO-DOSING DELIVERY OF PSYCHEDELICS DERIVATIVES | OPRL1, OPRM1, HTR2A | CHRM1 194/4885DRD2 16/4885KCNH2 401/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | CHRM1 3136/4885DRD2 2041/4885KCNH2 4304/4885 |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1501/4885DRD2 23/4885KCNH2 1457/4885 |
| US-20040180949-A1 | conjugates of pharmaceutical agents and a highly lipphilic group, a C22 unbranched carbon chain; render the activity of these compounds selective for colon tissue, breast tissue and central nervous system tissue | ALOX12, FABP2, ALOX15B | CHRM1 2463/4885DRD2 804/4885KCNH2 4205/4885 |
| US-20170226585-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1842/4885DRD2 31/4885KCNH2 1603/4885 |
| US-20120129940-A1 | METHODS OF TREATING AUTISM | GABRB3, GABRB2, GABBR1 | CHRM1 900/4885DRD2 1261/4885KCNH2 1578/4885 |
| US-20200399228-A1 | DREADD ACTUATORS | GRK1, GRK3, GRK2 | CHRM1 32/4885DRD2 373/4885KCNH2 1958/4885 |
| US-20110112159-A1 | SEROTONIN TRANSPORTER GENE AND TREAMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | CHRM1 2410/4885DRD2 52/4885KCNH2 3857/4885 |
| US-20120122986-A1 | Methods of Treating Fragile X Syndrome | GABRB1, GABBR1, GABBR2 | CHRM1 1690/4885DRD2 1473/4885KCNH2 1269/4885 |
| US-20080090803-A1 | FATTY ALCOHOL DRUG CONJUGATES | ADH1A, ADH1C, ADH5 | CHRM1 4096/4885DRD2 301/4885KCNH2 3644/4885 |
| US-20100076006-A1 | Topiramate Plus Naltrexone for the Treatment of Addictive Disorders | SLC6A3, SLC6A4, SLC6A2 | CHRM1 1360/4885DRD2 25/4885KCNH2 2086/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | CHRM1 97/4885DRD2 181/4885KCNH2 1578/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | CHRM1 4015/4885DRD2 1935/4885KCNH2 4633/4885 |
| US-20110105536-A1 | DOSING REGIMEN ASSOCIATED WITH LONG-ACTING INJECTABLE PALIPERIDONE ESTERS | CRH, LPXN, PRLHR | CHRM1 3909/4885DRD2 329/4885KCNH2 3695/4885 |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | CHRM1 31/4885DRD2 34/4885KCNH2 673/4885 |
| US-20130337031-A1 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS | SMURF1, SMURF2, SMS | CHRM1 917/4885DRD2 3054/4885KCNH2 3446/4885 |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ADRA2C, ADRB2, ADRA2A | CHRM1 54/4885DRD2 42/4885KCNH2 401/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CHRM1 4783/4885DRD2 3870/4885KCNH2 2949/4885 |
| US-20110183991-A1 | 5HT7 RECEPTOR LIGANDS AND COMPOSITIONS COMPRISING THE SAME | HTR7, HTR1A, HTR6 | CHRM1 182/4885DRD2 43/4885KCNH2 1091/4885 |
| US-20190002984-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF ALCOHOLISM | SLC6A4, SLC6A3, SLC6A2 | CHRM1 1842/4885DRD2 31/4885KCNH2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.